Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 5/20 | 0.43 |
| ▸ | BRAF | P15056 | 7/20 | 0.43 |
| ▸ | PIP4K2A | P48426 | 3/20 | 0.42 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765822 | 0.88 | XDH (0.40) | — | |
| SCHEMBL3765737 | 0.87 | KDR (0.40) | CYP11B2 | |
| SCHEMBL3778996 | 0.87 | KDR (0.37) | AKT1 | |
| SCHEMBL3774122 | 0.86 | XDH (0.39) | AKT1 | |
| SCHEMBL3772252 | 0.84 | EGLN1 (0.41) | CYP11B2 | |
| SCHEMBL3771008 | 0.83 | CHRNB1 (0.47) | — | |
| SCHEMBL3771012 | 0.83 | CHRNB1 (0.47) | — | |
| SCHEMBL3771510 | 0.82 | CTSA (0.36) | AKT1 | |
| SCHEMBL3775790 | 0.82 | CHRNB1 (0.40) | AKT1 | |
| SCHEMBL3774460 | 0.82 | CTSA (0.42) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | AKT1 1820/4885FYN 753/4885BRAF 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.